By Health In Five Writer
MFine in association with Datar Cancer Genetics has announced the launch of a Comprehensive Cancer Screening Programme on the MFine app. The introduced programme allows the booking of cancer screening tests on the MFine app to help patients detect cancer at an early stage. MFine users will be able to book the Datar EasyCheck360 (multiple cancers), EasyCheck FemmeSafe (women’s cancers) and EasyCheck Prostate cancer screening tests through the app. The partnership will also allow users to book the Datar EasyCheck Diabetes test.
EasyCheck is a radiation-free blood test for early cancer detection. It is clinically validated by one of the world’s largest clinical trials registered with the WHO clinical trial registry by Datar Cancer Genetics. The validation spans over 34,000 known cancer patients and more than 23,000 healthy individuals.
Early detection of cancer is vital for successful treatment and can help in successfully curing it at an early stage without the requirement of intensive and toxic treatments, subsequently also bringing down high treatment costs.
Viswanathan NS, CFO, MFine said, “Early Cancer screening & detection is key for higher survival rates, effective treatment and reduced costs. At MFine we believe in making quality healthcare more accessible and effective with the use of AI and mobile technologies. Towards that vision, the partnership with Datar will empower MFine users with access to early screening tests on their mobile. We will continue to invest in deep tech to transform every smartphone into a health companion for consumers and a decision support assistant to all doctors. We believe Smartphones as a health monitoring device will play a major role in the way users track their vital parameters and healthcare providers handle diagnostics.”
Samara Mahindra, Director-New Cancer Initiatives, Datar Cancer Genetics said, “The fastest way to eradicate cancer is to provide tests for early detection and screening. We need to understand that cancer can be treated effectively with an extremely high chance of survival, if detected early. Providing people with an easy and non-invasive way to screen is imperative to make this change and witness a cancer free India. Partnering with Mfine now creates accessibility to a large number of people who can screen themselves in the comfort of their homes.”